Colorectal cancer is the third most common form of cancer globally and the second most common cause of cancer deaths. The chance of a cure is high if the cancer is detected early enough, but early detection is not a given. Researchers from VIB and KU Leuven - together with various European oncology centers, including UZ Leuven - have identified bio-markers that can be incorporated in a new diagnostic test. This should make it possible to detect colorectal cancer at an early stage using a simple blood test. The results were published online on March xx, 2015 in Gut in an article titled “Tumour-Educated Circulating Monocytes Are Powerful Candidate Biomarkers for Diagnosis and Disease Follow-Up of Colorectal Cancer.” Dr. Max Mazzone (VIB/KU Leuven) commented: “This research demonstrates how important it is to gain a thorough understanding of the role of our immune system in cancer. In this case, this knowledge will hopefully result in a new, more sensitive test to detect colorectal cancer at an early stage, so that more patients can be cured. I hope that we can soon find an industrial partner to help us achieve the following step, which is the development of the test.” In 2012, a total of 1.4 million people worldwide were diagnosed with colorectal cancer, this figure is expected to increase to 2.4 million by 2035. This is a condition that affects a growing number of people each year. Colorectal cancer is very treatable if it is detected at an early stage, with approximately 95% chance of a cure. If detected at a late stage, however, the chance of surviving 5 years after diagnosis is less than 10 %. Therefore, it is very important to be able to detect the disease in an early stage. And therein lies the rub.
Login Or Register To Read Full Story